Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model.

AIMS We identified easily obtained baseline characteristics associated with outcomes in patients with chronic heart failure (HF) and elevated heart rate (HR) receiving contemporary guideline-recommended therapy in the SHIFT trial, and used them to develop a prognostic model. METHODS We selected the 10 best predictors for each of four outcomes (cardiovascular death or HF hospitalisation; all-cause mortality; cardiovascular mortality; and HF hospitalisation). All variables with p<0.05 for association were entered into a forward stepwise Cox regression model. Our initial analysis excluded baseline therapies, though randomisation to ivabradine or placebo was forced into the model for the composite endpoint and HF hospitalisation. RESULTS Increased resting HR, low ejection fraction, raised creatinine, New York Heart Association class III/IV, longer duration of HF, history of left bundle branch block, low systolic blood pressure and, for three models, age were strong predictors of all outcomes. Additional predictors were low body mass index, male gender, ischaemic HF, low total cholesterol, no history of hyperlipidaemia or dyslipidaemia and presence of atrial fibrillation/flutter. The c-statistics for the four outcomes ranged from 67.6% to 69.5%. There was no evidence for lack of fit of the models with the exception of all-cause mortality (p=0.017). Similar results were found including baseline therapies. CONCLUSION The SHIFT Risk Model includes simple, readily obtainable clinical characteristics to produce important prognostic information in patients with chronic HF, systolic dysfunction, and elevated HR. This may help better calibrate management to individual patient risk.

[1]  W. Kraus,et al.  Factors Related to Morbidity and Mortality in Patients With Chronic Heart Failure With Systolic Dysfunction: The HF-ACTION Predictive Risk Score Model , 2012, Circulation. Heart failure.

[2]  Karl Swedberg,et al.  Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.

[3]  J. McMurray,et al.  The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. , 2013, European heart journal.

[4]  M. Gold,et al.  Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial , 2011 .

[5]  C. O'connor,et al.  Heart failure in elderly patients: distinctive features and unresolved issues , 2013, European journal of heart failure.

[6]  M. Pfeffer,et al.  Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. , 2006, Journal of the American College of Cardiology.

[7]  Harlan M Krumholz,et al.  Renal impairment and outcomes in heart failure: systematic review and meta-analysis. , 2006, Journal of the American College of Cardiology.

[8]  S. Anker,et al.  The relationship between cholesterol and survival in patients with chronic heart failure. , 2003, Journal of the American College of Cardiology.

[9]  K. Swedberg,et al.  Risk following hospitalization in stable chronic systolic heart failure , 2013, European journal of heart failure.

[10]  E. Ferenczi,et al.  Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure , 2008, Heart.

[11]  Ankur Gupta,et al.  Ivabradine and outcomes in chronic heart failure , 2010, The Lancet.

[12]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[13]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[14]  W. Maisel,et al.  Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. , 2003, The American journal of cardiology.

[15]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[16]  I. Piña,et al.  Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate‐lowering properties , 2014, European journal of heart failure.

[17]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[18]  Helmut Baumgartner,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, European journal of heart failure.

[19]  L. Tavazzi,et al.  Predictors of Mortality in 6975 Patients With Chronic Heart Failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure Trial: Proposal for a Nomogram , 2013, Circulation. Heart failure.

[20]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[21]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[22]  G. W. Snedecor Statistical Methods , 1964 .

[23]  K. Dickstein,et al.  Aliskiren, ALTITUDE, and the implications for ATMOSPHERE , 2012, European journal of heart failure.

[24]  E. Vartiainen,et al.  Simplifying cardiovascular risk estimation using resting heart rate. , 2010, European heart journal.

[25]  G. Guyatt,et al.  Risk Prediction Models for Mortality in Ambulatory Patients With Heart Failure: A Systematic Review , 2013, Circulation. Heart failure.

[26]  E. Braunwald Chronic heart failure: a look through the rear view mirror. , 2013, European heart journal.

[27]  R. Califf,et al.  Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. , 2000, The American journal of cardiology.

[28]  Anna Strömberg,et al.  ESC GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF ACUTE AND CHRONIC HEART FAILURE 2008 (ENDING) , 2009 .

[29]  John G F Cleland,et al.  Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. , 2007, Journal of cardiac failure.

[30]  K. Swedberg,et al.  Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT) , 2010, European journal of heart failure.

[31]  Kamyar Kalantar-Zadeh,et al.  Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. , 2004, Journal of the American College of Cardiology.

[32]  Luigi Tavazzi,et al.  Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. , 2002, American heart journal.

[33]  Karl Swedberg,et al.  Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients , 2005, Circulation.

[34]  S. Anker,et al.  Revisiting the obesity paradox in heart failure: new insights? , 2011, European journal of heart failure.